c6 ceramide

C6 Ceramide (N-hexanoylsphingosine) is an activator of the ceramide pathway that arrests cells in the G0/G1 phase by activating ERK. It can act in a variety of cancer cell lines.

ω-azido-C6 Ceramide reduces membrane potential and exhibits antibacterial activity against Neisseria, with a minimum inhibitory concentration (MIC) of 2 µg/mL for N. meningitidis MC58 and N. gonorrhoeae FA1090.

C6 Ceramide (d18:1/6:0) alkyne is an ω-alkyne derivative of C6 ceramide. The terminal alkyne group enables it to participate in click chemistry reactions, facilitating the labeling of C6 ceramide with fluorescent tags or biotin. This allows for analysis of C6 ceramide's metabolism and biological activity.

Photoclick C6 ceramide is a clickable sphingolipid.

C6 L-erythro Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is metabolized by ceramide glucosyltransferase to form C6 L-erythro glucosylceramide. C6 L-erythro Ceramide is cytotoxic to U937 cells (IC50 = 18 μM).

C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells in vitro (IC50 = 18 μM), metabolically inactive, and unlike C6 L-erythro ceramide, it cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 L-threo Ceramide enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells at 10 μM.

C6 urea ceramide is an inhibitor of neutral ceramidase.1 It increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and in HT-29 colon cancer cells but not in MEFs lacking neutral ceramidase. It inhibits proliferation of, and induces apoptosis and autophagy in HT-29, but not non-cancerous RIE-1, cells when used at concentrations of 5 and 10 μM. C6 urea ceramide decreases total β-catenin, increases phosphorylated β-catenin, and induces colocalization of β-catenin with the 20S proteasome in HT-29 and HCT116, but not RIE-1, cells. It reduces tumor growth and increases C16, C18, C20, and C24 ceramide levels in tumor tissue in an HT-29 mouse xenograft model when administered at doses of 1.25, 2.5, and 5 mg/kg for five days. |1. García-Barros, M., Coant, N., Kawamori, T., et al. Role of neutral ceramidase in colon cancer. FASEB J. 30(12), 4159-4171 (2016).

C6 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides., C6 D-threo Ceramide is cytotoxic to U937 cells in vitro (IC50 = 18 μM). It is metabolically inactive and, unlike C6 L-erythro ceramide , C6 D-threo ceramide cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 D-threo Ceramide promotes survival of isolated rat spinal neurons when used at concentrations up to 2.5 μM but induces cell death at concentrations greater than 5 μM. It enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells when used at a concentration of 10 μM.

C6 dihydro Ceramide (d18:0/6:0) is a lipid molecule that can be used in life science related research. The CAS number of C6 dihydro Ceramide (d18:0/6:0) is 171039-13-7.

C6 Biotin Ceramide (d18:1/6:0) is a lipid molecule that can be used in life science related research. The CAS number of C6 Biotin Ceramide (d18:1/6:0) is 192070-02-3.

C6 Phytoceramide (t18:0/6:0) is a lipid molecule that can be used in life science related research. The CAS number of C6 Phytoceramide (t18:0/6:0) is 249728-94-7.

C6 Dihydro 1-deoxyceramide (m18:0/6:0) (C6 Dihydro ceramide (m18:0/6:0)) is an analogue of ceramide.

C6 1-Deoxyceramide (m18:1/6:0) (C6:0 Ceramide (m18:1/6:0)) is a non-typical short-chain ceramide.

C6 1-Deoxyceramide (m18:1(14Z)/6:0) (Ceramide (m18:1(14Z)/6:0)) is a type of short-chain ceramide that includes 1-Deoxysphingosine (m18:1(14Z)).